Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Overview Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Companies Involved in Therapeutics Development Advinus Therapeutics Ltd AstraZeneca Plc CymaBay Therapeutics Inc Dompe Farmaceutici SpA GlaxoSmithKline Plc Merck & Co Inc Sancilio & Company Inc Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Drug Profiles CB-001 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-137647A - Drug Profile Product Description Mechanism Of Action R&D Progress SC-410 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize FFAR4 for Type 2 Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize FFA4 for Unspecified Indication - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize GPR-120 for Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize GPR120 for Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize GPR120 for Type 2 Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Dormant Products Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Advinus Therapeutics Ltd, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by CymaBay Therapeutics Inc, H1 2017 Pipeline by Dompe Farmaceutici SpA, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Pipeline by Merck & Co Inc, H1 2017 Pipeline by Sancilio & Company Inc, H1 2017 Dormant Projects, H1 2017 List of Figures Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products by Mechanism of Actions, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Molecule Type, H1 2017

Advinus Therapeutics Ltd AstraZeneca Plc CymaBay Therapeutics Inc Dompe Farmaceutici SpA GlaxoSmithKline Plc Merck & Co Inc Sancilio & Company Inc